Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the Eye

Not Applicable

Conditions: Retinoblastoma

First Posted Date: 2006-08-07

Last Posted Date: 2013-09-17

Lead Sponsor: Children's Cancer and Leukaemia Group

Registration Number: NCT00360750

Locations: 🇬🇧
Leicester Royal Infirmary, Leicester, England, United Kingdom
🇬🇧
Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland, United Kingdom
🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom

and more 9 locations

Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders

Phase 1

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Basophilic Leukemia
Adult Acute Eosinophilic Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Interventions: Drug: vorinostat
Drug: cytarabine
Drug: etoposide
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2006-07-27

Last Posted Date: 2013-05-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00357305

Locations: 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

Phase 1

Terminated

Conditions: Anaplastic Large Cell Lymphoma
Recurrent Childhood Anaplastic Large Cell Lymphoma

Interventions: Biological: monoclonal antibody SGN-30
Drug: therapeutic hydrocortisone
Drug: ifosfamide
Drug: carboplatin
Drug: etoposide
Drug: methotrexate
Drug: cytarabine
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2006-07-20

Last Posted Date: 2018-03-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5

Registration Number: NCT00354107

Locations: 🇺🇸
Children's Oncology Group, Philadelphia, Pennsylvania, United States

VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia

Phase 2

Conditions: Leukemia

First Posted Date: 2006-07-20

Last Posted Date: 2014-01-10

Lead Sponsor: Vion Pharmaceuticals

Target Recruit Count: 85

Registration Number: NCT00354276

Locations: 🇫🇷
Hopital Haut Leveque, Pessac, France
🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
🇬🇧
University Hospital of Wales, Cardiff, Wales, United Kingdom

Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: cyclophosphamide
Drug: carmustine
Procedure: peripheral blood stem cell transplantation
Radiation: irradiation therapy
Drug: etoposide
Biological: G-CSF
Drug: Cytarabine

First Posted Date: 2006-06-29

Last Posted Date: 2020-07-14

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 473

Registration Number: NCT00345865

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia

Not Applicable

Conditions: Leukemia

First Posted Date: 2006-06-23

Last Posted Date: 2013-08-26

Lead Sponsor: Universitätsklinikum Hamburg-Eppendorf

Target Recruit Count: 550

Registration Number: NCT00343369

Locations: 🇩🇪
Dr. von Haunersches Kinderspital der Universitaet Muenchen, Munich, Germany
🇩🇪
Kreskrankenhaus Kinderabteilung, Heide, Germany
🇩🇪
Universitaets - Kinderklinik, Leipzig, Germany

and more 13 locations

S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: clofarabine
Drug: cytarabine

First Posted Date: 2006-06-15

Last Posted Date: 2015-03-25

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 36

Registration Number: NCT00337168

Locations: 🇺🇸
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
CCOP - Montana Cancer Consortium, Billings, Montana, United States
🇺🇸
Charles B. Eberhart Cancer Center at DeKalb Medical Center, Decatur, Georgia, United States

and more 88 locations

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Biological: Rituximab
Drug: Cytarabine
Drug: Dexamethasone
Drug: Leucovorin
Drug: Methotrexate
Drug: Procarbazine
Drug: Vincristine

First Posted Date: 2006-06-08

Last Posted Date: 2023-07-03

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 26

Registration Number: NCT00335140

Locations: 🇺🇸
West Michigan Cancer Center, Kalamazoo, Michigan, United States
🇺🇸
Minnesota Oncology Hematology, PA - Woodbury, Woodbury, Minnesota, United States
🇺🇸
Bronson Methodist Hospital, Kalamazoo, Michigan, United States

and more 65 locations

A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)

Phase 3

Completed

Conditions: Acute Myelogenous Leukemia

Interventions: Drug: clofarabine (IV formulation)
Drug: placebo
Drug: cytarabine

First Posted Date: 2006-04-25

Last Posted Date: 2014-04-14

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 326

Registration Number: NCT00317642

Locations: 🇺🇸
Evanston Northwestern Healthcare, Evanston, Illinois, United States
🇺🇸
Stanford Comprehensive Cancer Center, Stanford, California, United States
🇺🇸
Mt. Sinai School of Medicine, New York, New York, United States

and more 54 locations

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

Not Applicable

Conditions: Lymphoma

First Posted Date: 2006-04-24

Last Posted Date: 2015-09-25

Lead Sponsor: European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma

Target Recruit Count: 96

Registration Number: NCT00317408

Locations: 🇨🇿
University Hospital Brno, Brno, Czech Republic
🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
🇩🇪
Krankenhaus Muenchen Schwabing, Munich, Germany

and more 91 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy